The effectiveness of immunosuppressive cyclosporin in attenuating the progression of interstitial lung diseases

Interstitial lung diseases (ILDs) are a group of diseases that affects the lung parenchymal tissue causing irreversible damage through fibrosis and chronic inflammation, consequentially depriving gas exchange in affected individuals (1). The effects in ILDs are observed largely in the lung interstitium and differentiating them from one other is often challenging as they often share comparable physiological, clinical and radiological features (2).